Targeted Cancer Therapies Have Become a New Way of Treating Cancer with Personalized Medicine or Precision Medicine

Targeted Cancer Therapies are drugs that attack cancer cells in very specific ways. They are part of a new way to treat cancer called precision medicine or personalized medicine, which is based on the idea that patients are more likely to respond to treatments when they are tailored to the unique genetic changes in their tumors. Targeted cancer therapies block signals that tell cancer cells to grow and divide too quickly, or they may stop the cancer from growing at all by killing it. They can be given in pill form, through an IV drip or by injection under the skin.

They are usually given along with other treatments such as chemotherapy and immunotherapy, which boost the immune system’s ability to kill cancer cells. Some targeted cancer therapies can be used to help other treatments work better, such as boosting the effect of radiation therapy by interfering with how it reaches cancer cells. Cancer develops when normal cells change their genes, allowing them to become out of control and multiply quickly. This is known as a mutation, and about 5-10% of all cancers are caused by genetic changes passed down from parents to children.

According to Coherent Market Insights the Targeted Cancer Therapies Market Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028.

The most common types of targeted cancer drugs are signal transduction inhibitors, apoptosis inducers and anti angiogenic agents (which block the growth of blood vessels that cancer cells need to get nutrients and oxygen). Other drugs, such as those that target the epidermal growth factor receptor (EGFR) or the HER2 protein, may also be effective in treating breast, lung and colon cancers.

The first step in testing a drug is to find the right target, which is usually a protein that is found only in cancer cells and not in healthy cells. This is a process called biomarker analysis. Pathologists use this method to find these proteins in the patient’s tumor and then test it for a match with a medication. In August 2022, the U.S. Food and Drug Administration granted approval to the first targeted therapy for individuals suffering from HER2-low breast cancer, which cannot be removed by surgery.

Comments

Popular posts from this blog

Rising Adoption of AI in companies to boost AI Governance Market Growth

The Increasing Demand for Secure and Confidential Communication Is Boosting the Signal Jammer Market Growth

Wearable Injector are Devices Which Adhere to the Body and Help in Administering Drug to the Patient